+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pharyngeal Cancer Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023 - Product Image

Pharyngeal Cancer Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

  • ID: 4845503
  • Report
  • September 2019
  • Region: Global
  • 153 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
Global Pharyngeal Cancer Market: About this market
The pharyngeal cancer market analysis considers sales from targeted therapy and chemotherapy products. Our analysis also considers the sales of pharyngeal cancer in Asia, Europe, North America, and ROW. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the development of novel targeted therapies will play a significant role in the targeted therapy segment to maintain its market position. Also, our global pharyngeal cancer market report looks at factors such as high-risk factors for pharyngeal cancer, increasing geriatric population, and increasing awareness of pharyngeal cancer. However, availability of alternative treatment options, adverse effects of chemotherapy, and high cost of targeted therapy may hamper the growth of the pharyngeal cancer industry over the forecast period.

Global Pharyngeal Cancer Market: Overview

High-risk factors for pharyngeal cancer
Pharyngeal cancer is one of the most common types of cancer as it largely attributed to the prevalence of high-risk factors such as increase in the use of tobacco, excessive alcohol consumption, increase in viral infections, and occupational exposure. Viral infections associated with the throat can lead to the development of throat cancer, including pharyngeal cancer. Moreover, individuals working in high-dose radiation environments can also develop pharyngeal cancer as they are exposed to certain chemicals, dust, or fumes. Thus, such high-risk factors for pharyngeal cancer will lead to the expansion of the global pharyngeal cancer market at a CAGR of over 6% during the forecast period.

Emergence of pipeline molecules
Despite the high prevalence of pharyngeal cancer, there is a lack of approved targeted therapy drugs for treatment. This is encouraging vendors to invest significantly in the development of novel therapeutics with limited side effects. For instance, Roche is developing TECENTRIQ, which is a novel PD-L1 monoclonal antibody to prevent cancer immune evasion. The filing of this molecule is expected in 2022, and it is expected to receive marketing approval by the end of the forecast period. Similarly, AstraZeneca is also conducting clinical trials of durvalumab, a PD-L1 molecule in combination with different drugs.  Thus, the expected approvals of the late-stage pipeline molecules are anticipated to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the global pharyngeal cancer market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pharyngeal cancer manufacturers, that include AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Also, the pharyngeal cancer market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Emergence of pipeline molecules
  • Presence of reimbursement and patient assistance programs
  • Advent of novel therapies
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Adverse effects of common chemotherapy drugs
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AstraZeneca Plc - Vendor overview
Exhibit 50: AstraZeneca Plc - Business segments
Exhibit 51: AstraZeneca Plc - Organizational developments
Exhibit 52: AstraZeneca Plc - Geographic focus
Exhibit 53: AstraZeneca Plc - Key offerings
Exhibit 54: AstraZeneca Plc - Key customers
Exhibit 55: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 56: Bristol-Myers Squibb Co. - Business segments
Exhibit 57: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 58: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 59: Bristol-Myers Squibb Co. - Key offerings
Exhibit 60: Bristol-Myers Squibb Co. - Key customers
Exhibit 61: Eli Lilly and Co. - Vendor overview
Exhibit 62: Eli Lilly and Co. - Business segments
Exhibit 63: Eli Lilly and Co. - Organizational developments
Exhibit 64: Eli Lilly and Co. - Geographic focus
Exhibit 65: Eli Lilly and Co. - Segment focus
Exhibit 66: Eli Lilly and Co. - Key offerings
Exhibit 67: Eli Lilly and Co. - Key customers
Exhibit 68: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 69: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 70: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 71: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 72: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 73: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 74: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 75: Merck & Co. Inc. - Vendor overview
Exhibit 76: Merck & Co. Inc. - Business segments
Exhibit 77: Merck & Co. Inc. - Organizational developments
Exhibit 78: Merck & Co. Inc. - Geographic focus
Exhibit 79: Merck & Co. Inc. - Segment focus
Exhibit 80: Merck & Co. Inc. - Key offerings
Exhibit 81: Merck & Co. Inc. - Key customers
Exhibit 82: Mylan NV - Vendor overview
Exhibit 83: Mylan NV - Product segments
Exhibit 84: Mylan NV - Organizational developments
Exhibit 85: Mylan NV - Geographic focus
Exhibit 86: Mylan NV - Segment focus
Exhibit 87: Mylan NV - Key offerings
Exhibit 88: Mylan NV - Key customers
Exhibit 89: Pfizer Inc. - Vendor overview
Exhibit 90: Pfizer Inc. - Business segments
Exhibit 91: Pfizer Inc. - Organizational developments
Exhibit 92: Pfizer Inc. - Geographic focus
Exhibit 93: Pfizer Inc. - Segment focus
Exhibit 94: Pfizer Inc. - Key offerings
Exhibit 95: Pfizer Inc. - Key customers
Exhibit 96: Sanofi - Vendor overview
Exhibit 97: Sanofi - Business segments
Exhibit 98: Sanofi - Organizational developments
Exhibit 99: Sanofi - Geographic focus
Exhibit 100: Sanofi - Segment focus
Exhibit 101: Sanofi - Key offerings
Exhibit 102: Sanofi - Key customers
Exhibit 103: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 104: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 105: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 106: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 108: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 115: Validation techniques employed for market sizing
Exhibit 116: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll